English
Back
Download
Log in to access Online Inquiry
Back to the Top

$Iterum Therapeutics (ITRM.US)$ its almost bout time. Thera...

$Iterum Therapeutics (ITRM.US)$ its almost bout time.
Therapeutics plc's (NASDAQ:ITRM)future prospects. Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. With the latest financial year loss of US$38m and a trailing-twelve-month loss of US$28m, the US$20m market-cap company alleviated its loss by moving closer towards its target of breakeven. The most pressing concern for investors is Iterum Therapeutics' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
Expectations from some of the American Pharmaceuticals analysts is that Iterum Therapeutics is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of US$73k in 2026. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 73%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
5
+0
Translate
Report
7102 Views
Comment
Sign in to post a comment
    Investment has made me a millionaire. How about you?
    99
    Followers
    13
    Following
    576
    Visitors
    Follow